Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. - Wikidata - awgldk - TriplyDB

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.

http://www.wikidata.org/entity/Q35098320

about

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.

http://www.wikidata.org/entity/Q35098320

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Effect of adjuvant trastuzumab ...... ER2-based neoadjuvant therapy.

@ast

Effect of adjuvant trastuzumab ...... ER2-based neoadjuvant therapy.

@en

type

label

Effect of adjuvant trastuzumab ...... ER2-based neoadjuvant therapy.

@ast

Effect of adjuvant trastuzumab ...... ER2-based neoadjuvant therapy.

@en

prefLabel

Effect of adjuvant trastuzumab ...... ER2-based neoadjuvant therapy.

@ast

Effect of adjuvant trastuzumab ...... ER2-based neoadjuvant therapy.

@en

P1433

Q35098320-E289E446-EC9C-4934-9691-3783EDCFB58B

P1476

Q35098320-B656EE84-48F9-40C9-A206-729374997C70

P2093

Q35098320-17D2205E-4A7D-4FD1-9774-55F1A9C33C6B

Q35098320-210ACE4D-3DE3-4AC2-9319-5C128276B546

Q35098320-5F5C8372-A043-445F-A4AC-CB0E5F42B2C4

Q35098320-894EF04D-9A7D-4634-A70A-E907415F1877

Q35098320-90A796A9-8750-4A87-8791-979DD0D14A3F

Q35098320-E28E40FA-6EEB-4A3D-8AFC-8697749EEEFF

Q35098320-EFBBFE94-4C66-417D-8E6B-E62B13BC0D65

Q35098320-F793DF0A-6D1C-447E-96A6-84613BC3D7AA

P2860

Q35098320-033D36D7-A071-4CF9-B474-128FE9E82908

Q35098320-0A066A72-7D16-43E6-9D9C-2E14C238D6F0

Q35098320-0C7B1F9E-7C0C-48DB-AC69-3818943ECD45

Q35098320-181C3D9B-5C29-46B3-AF88-5E84F77643E3

Q35098320-25962A8B-A325-48F8-B77C-D76ED66DEA3E

Q35098320-25B29549-36BF-4D81-900E-E0F21250B188

Q35098320-42C45DE0-D6EB-4B87-AC72-F5F4E4D9C64B

Q35098320-5946616F-1B07-499B-B1A9-D5A55D4BB2E1

Q35098320-7ABF6CCD-6DF2-414D-A191-2B017111209D

Q35098320-7E5DEC2B-7058-4ACA-B750-276047491DAC

P2888

Q35098320-F7430A01-56D4-4781-9625-43088076B46E

P304

Q35098320-FA1E1CCA-3BBF-4540-8869-F6BFC4A788FB

P31

Q35098320-29F6600D-9556-48AF-8080-0B85BA2C62B8

P356

Q35098320-11D18414-828F-4D2B-B6E9-A4DA97CE162C

P407

Q35098320-3CE92A00-D8AA-47CD-8D74-F0D4F0ABF251

P433

Q35098320-830960F7-A6F4-4DD7-B3C8-05BB76D958A3

P478

Q35098320-3003C70D-21CD-462F-8AA3-7A21BB4C5908

P50

Q35098320-89A49648-2BA7-4466-9B88-8308B44AD089

P577

Q35098320-97708EEE-7E4B-4E28-A685-4AFE9FF32043

P698

Q35098320-143EE3B5-8FF4-4428-8330-3102C44AE8F5

P932

Q35098320-414DE863-30BB-4D62-9AC0-B81A9163FD4A

P356

P1433

British Journal of Cancer

P1476

Effect of adjuvant trastuzumab ...... HER2-based neoadjuvant therapy

@en

P2093

A M Gonzalez-Angulo

http://www.w3.org/2001/XMLSchema#string

E A Mittendorf

http://www.w3.org/2001/XMLSchema#string

G N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

H Zhang

http://www.w3.org/2001/XMLSchema#string

K K Hunt

http://www.w3.org/2001/XMLSchema#string

N Parinyanitikul

http://www.w3.org/2001/XMLSchema#string

V Valero

http://www.w3.org/2001/XMLSchema#string

X Lei

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).

P2888

P304

630-635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.647

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Mariana Chavez-MacGregor

P577

2015-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25584488

http://www.w3.org/2001/XMLSchema#string

P932

4333494

http://www.w3.org/2001/XMLSchema#string